A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

The Sponsor is studying an investigational medication called danicamtiv to determine if it can help people with genetic and familial dilated cardiomyopathy (DCM). Investigational means that the safety and effectiveness of danicamtiv have not been established. Currently, there are no approved drugs that are designed specifically to treat genetic or familial DCM.
The purpose of this study is to evaluate how well danicamtiv works compared to a placebo (sugar pill that looks like danicamtiv pill but does not contain any danicamtiv) and see how safe it is for people with genetic and familial DCM. In DCM, the heart muscle weakens and enlarges, making it harder for the heart to pump blood and can happen for different reasons. Some people have DCM because of a change in a gene (called genetic DCM). Others may have DCM that runs in their family, even if no specific gene change is found (called familial DCM).
The main goals of the study are:
* To assess the effect of danicamtiv on cardiac function using echocardiogram.
* To evaluate the impact of danicamtiv on exercise capacity
* To evaluate the safety and tolerability of danicamtiv
Participants will:
* Take danicamtiv or placebo every day for approximately 6 months
* Visit the clinic about 12 times for initial evaluation, checkups, tests and follow up

Start Date01 Nov 2025

Sponsor / Collaborator

Kardigan, Inc.

NCT06027437

/ CompletedPhase 1

A Phase 1, Open-label, Randomized, Single-dose, 3-Period, 3-Sequence Crossover Study to Assess the Relative Bioavailability of the Intended Commercial Formulation Versus the Previous MyoKardia Formulation of Danicamtiv and to Assess the Effect of Food on the Pharmacokinetics of the Intended Commercial Formulation in Healthy Adult Participants

The purpose of this study is to assess the relative biological availability and the effect of food on the drug levels of Danicamtiv in health adults.

Start Date05 Sep 2023

Sponsor / Collaborator

Bristol Myers Squibb Co.

NCT05952089

/ CompletedPhase 1

An Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of Danicamtiv on the Pharmacokinetics of Midazolam in Patients With Stable Heart Failure With Reduced Ejection Fraction

The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).

Start Date17 Aug 2023

Sponsor / Collaborator

Bristol Myers Squibb Co.

100 Clinical Results associated with Danicamtiv

100 Translational Medicine associated with Danicamtiv

100 Patents (Medical) associated with Danicamtiv

Literatures (Medical) associated with Danicamtiv

01 Oct 2025·JOURNAL OF PHYSIOLOGY-LONDON

Danicamtiv increases cardiac mechanical efficiency

Article

Author: Taberner, Andrew J. ; Han, June‐Chiew ; Tran, Kenneth ; Meehan, Trent ; Pham, Toan

Abstract:

Danicamtiv is a recently developed cardiac‐specific myosin activator that directly increases actomyosin interaction and, thereby, increases force. It is currently studied pre‐clinically and has entered clinical trials. In this study, we provide the first assessment of its effects on cardiac energetics. Ventricular trabeculae from rats were isolated and studied in vitro. Each trabecula was stimulated to produce twitch force over ranges of muscle lengths and afterloads, with muscle heat output simultaneously measured. Each trabecula was superfused with and without danicamtiv (5 µM). In both interventions, muscles were required to undergo both isometric and work‐loop contraction protocols to quantify the components of heat output – that from muscle contraction, that from intracellular Ca2+ cycling and that from actomyosin cross‐bridge cycling. Danicamtiv was found to increase twitch force, muscle heat and cross‐bridge heat, with no effect on the energy expenditure associated with intracellular Ca2+ cycling. Danicamtiv slowed isometric twitch force kinetics and slowed shortening kinetics. Danicamtiv increased the extent of muscle shortening, increased muscle work output and increased mechanical efficiency, while preserving cross‐bridge efficiency. In conclusion, danicamtiv increases mechanical efficiency, the mechanism of which arises from the greater increase of force and muscle shortening that increase mechanical work than the increase of heat. The relative smaller increase of heat is due to a null effect of danicamtiv on the energy for intracellular Ca2+ cycling. Our results provide perspective for the utility of danicamtiv as an inotropic agent not only for mechanical enhancement but also for energetic enhancement in increasing mechanical efficiency. image

Key points:

Clinical trials are presently exploring the potential of a new myotrope, danicamtiv, to improve cardiac mechanics by increasing muscle force output.A range of active pre‐clinical research is likewise uncovering the biophysical mechanism of how danicamtiv affects cardiac mechanics, increases cardiac force and slows contractile kinetics.This study provides the first energetic assessment of danicamtiv by measuring muscle heat output, and shows that danicamtiv increases cardiac energy efficiency. The mechanism of the increased efficiency resides in the increase of muscle force–length work greater than the increase of muscle heat.This study demonstrates that danicamtiv is a cardiac myotrope that not only enhances mechanics, but also exerts its enhancement effect on energetics.

26 Aug 2025·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Danicamtiv reduces myosin’s working stroke but activates the thin filament by accelerating actomyosin attachment

Article

Author: Greenberg, Lina ; Squarci, Caterina ; Scott, Brent ; Greenberg, Michael J. ; Campbell, Kenneth S.

Heart failure is a leading cause of death worldwide, and even with current treatments, the 5-y transplant-free survival rate is only ~50 to 70%. As such, there is a need to develop new treatments for patients that improve survival and quality of life. Recently, there have been efforts to develop small molecules for heart failure that directly target components of the sarcomere, including cardiac myosin. Danicamtiv is one of these molecules; however, its direct effects on myosin’s single molecule mechanics and kinetics are not well understood. Using optical trapping techniques, stopped flow transient kinetics, and in vitro reconstitution assays, we found that danicamtiv reduces the size of cardiac myosin’s working stroke without affecting actomyosin detachment kinetics at the level of individual crossbridges. We demonstrate that danicamtiv accelerates actomyosin association kinetics, leading to increased recruitment of myosin crossbridges and subsequent thin filament activation at physiologically relevant calcium concentrations. We demonstrate important mechanistic differences with another cardiac myosin binding myotrope, omecamtiv mecarbil. Finally, we computationally model how the observed changes in mechanics and kinetics at the level of single crossbridges can contribute to increased cardiac contraction. Taken together, our results have important implications for the design of sarcomeric-targeting compounds for heart failure.

07 Jul 2025·JOURNAL OF GENERAL PHYSIOLOGY

Comparative mechanistic analysis of danicamtiv and omecamtiv mecarbil’s in vivo cardiac effects

Article

Author: Stelzer, Julian E. ; Holmes, Joshua B.

Danicamtiv is a second-generation myotropic sarcomere activator currently in clinical trials for treating heart failure with reduced ejection fraction. Initial clinical and preclinical studies suggest that danicamtiv improves upon the major shortcoming of the first-generation myotropic sarcomere activator, omecamtiv mecarbil (OM), which overly impaired diastolic function. However, no study has directly compared the in vivo cardiac effects of danicamtiv and OM to verify these claims. These direct comparisons are essential to understand the potential benefits of one drug over the other. Therefore, this study employed carefully controlled experiments with left ventricular pressure–volume loop and echocardiographic strain analysis to compare how danicamtiv and OM alter each phase of the cardiac cycle. Our results show that for similar increases in left ventricular stroke volume, danicamtiv reduced diastolic performance and myocardial relaxation less than OM. However, danicamtiv still significantly decreased diastolic function at higher doses, like OM. Furthermore, danicamtiv and OM elicited a qualitatively similar triphasic dose–response from the left ventricle. These similarities between danicamtiv and OM in the whole heart were surprising given recent evidence showing significant differences in the drugs’ molecular effects on myosin mechanics. We therefore conclude that danicamtiv likely has a wider therapeutic window than OM, but may be limited by the same trade-off between systolic and diastolic performance, driven by similar underlying mechanisms.

News (Medical) associated with Danicamtiv

25 Sep 2025

·www.businesswire.com

Kardigan Advances Late-Stage Portfolio of Personalized Cardiovascular Medicines in Dilated Cardiomyopathy, Acute Severe Hypertension and Calcific Aortic Valve Stenosis

SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, a heart health company modernizing cardiovascular drug development, today introduced the three late-stage clinical programs leading its robust pipeline, each strategically chosen to advance the Company’s mission of delivering multiple important medicines at a pace not previously seen in cardiology. These programs target the underlying drivers of specific types of dilated cardiomyopathy (DCM), acute severe hypertension (ASH) and calcific aortic valve stenosis (CAVS), where no treatments exist. For decades, cardiovascular disease has been the number one cause of death worldwide.1,2 In the U.S. alone, it claims more lives than all cancers and accidents combined.3 Despite this, conventional approaches to drug development, intermittent industry focus, and limited investment have resulted in incremental therapeutic advancements with minimal improvement in patient outcomes overall. “To create meaningful change for patients suffering from cardiovascular diseases, we need to think differently about how we develop new drugs,” said Tassos Gianakakos, co-founder, chief executive officer, and chair of Kardigan. “At Kardigan, we are uniting real-world patient data, AI insights and deep cardiovascular expertise to advance therapies with the potential to transform outcomes. Each of our therapeutic candidates is designed to address a specific subset of patients in key disease areas where we believe it is possible to halt disease progression or even deliver a functional cure. We are grateful for the continued support of our clinical collaborators who share our conviction that the time is now to pioneer a new scientific strategy aimed at making cardiovascular disease preventable, curable and no longer the leading cause of death in the world.” Kardigan has curated a diverse pipeline with three late-stage clinical programs, each designed to move beyond symptom management and to redefine treatment approaches where patients and their families need it most. Collectively, the programs create opportunities to generate new clinical insights and data that will fuel Kardigan’s ongoing R&D and discovery efforts beyond these three disease areas. Supported by the integration of Prolaio’s AI and real-world data platform, Kardigan is enhancing its ability to generate insights that can inform trial design and potentially reduce the time and cost to develop meaningful new medicines. Kardigan’s three most advanced programs include: DCM : a cardiac muscle disorder that carries significant risk of disease progression to advanced stages of heart failure. Despite the availability of treatments to address symptoms, there are no therapies that specifically reduce or reverse the progression of DCM pathophysiology. Kardigan is advancing danicamtiv , a potential first-in-class cardiac myosin activator targeting genetic DCM driven by sarcomeric mutations, to restore cardiac function through direct activation of both atrial and ventricular function. Data from a Phase 2a study of danicamtiv will be presented in a late-breaking oral session at the Heart Failure Society of America Annual Scientific Meeting 2025 on September 29, starting at 9:00 AM CT. Kardigan in-licensed exclusive worldwide development and commercialization rights to danicamtiv, an investigational drug discovered at MyoKardia and further developed by Bristol Myers Squibb. ASH : a sudden and severe spike in blood pressure requiring immediate attention to prevent heart attack, stroke or damage to other organs. While many patients who develop ASH have underlying chronic hypertension, the near-term risk associated with this acute event is underappreciated and rarely studied as a disease condition. There are currently no treatments indicated for ASH. Kardigan is developing tonlamarsen as an angiotensinogen-targeted bridging therapy to interrupt the dangerous cycle of ASH, with the potential to lower blood pressure and reduce risks of organ damage, heart failure and other serious cardiovascular events. Kardigan in-licensed exclusive worldwide development and commercialization rights to tonlamarsen, an investigational drug discovered and developed by Ionis. CAVS : calcium buildup on the aortic valve is the leading cause of aortic stenosis in adults in the U.S. and EU. 4 There is a critical unmet need for treatment that can mitigate valve replacement surgery, a challenge compounded by limited understanding of the biology driving valvular calcification. Kardigan is developing ataciguat , a once-daily, oral soluble guanylate cyclase activator, as a potential first-in-class treatment for CAVS and an alternative to the current ‘watchful waiting’ approach and progression to valve replacement that is today’s standard of care. Kardigan acquired rights to ataciguat, an investigational drug developed by, and in-licensed from, Sanofi and Mayo Clinic. “Our portfolio has been carefully designed to align with Kardigan’s criteria for developing synergistic therapies that target critical disease drivers, in each case with the potential to move beyond symptom management to functional cures,” said Jay Edelberg, M.D., Ph.D., co-founder and chief medical officer. “With ample opportunity for learning across programs, we believe Kardigan’s cardiac intelligence platform will drive effective patient segmentation, streamline clinical trials and ultimately deliver novel therapies to patients who have the potential to benefit most.” 1 Di Cesare M, Perel P, Taylor S, et al. “The heart of the world.” Global Heart, vol. 19, no. 1, 2024, p. 11. doi:10.5334/gh.1288. 2 World Health Organization. “Cardiovascular Diseases (CVDs).” WHO Fact Sheets, 31 July 2025. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29 3 Martin SS, Aday AW, Allen NB, et al. “Heart disease and stroke statistics: A report of US and global data from the American Heart Association.” Circulation, vol. 151, no. 8, 2025, pp. e41–e660. doi:10.1161/CIR.0000000000001303. 4 Christensen JL, Tan S, Chung HE, et al. “Aortic valve calcification predicts all-cause mortality independent of coronary calcification and severe stenosis.” Atherosclerosis, vol. 307, 2020, pp. 16–20. https://doi.org/10.1016/j.atherosclerosis.2020.06.019.Christensen et al., Atherosclerosis, 2020 About Kardigan Kardigan is a patient-driven heart health company that is modernizing cardiovascular drug development to deliver medicines that move patients beyond symptom management to functional cures. By matching critical disease drivers with treatment responders identified in clinical trials, Kardigan is developing a portfolio of medicines with the potential to modify the underlying cardiovascular disease pathophysiology to get patients closer to the cures they deserve. The company is based in South San Francisco, California and Princeton, New Jersey. To learn more, visit Kardigan.bio.

AHAPhase 2License out/in

25 Sep 2025

·endpoints.news

Kardigan gets the rights to a MyoKardia drug; Lilly stops Phase 2 trial for muscle-sparing candidate

Plus, news about uniQure, MBX Biosciences, KalVista, Volastra, Basilea Pharmaceutica, Gossamer Bio, Respira Therapeutics, Sanofi, Immuneering and Heidelberg Pharma: 🫀 Kardigan reveals its pipeline: The cardiovascular biotech has in-licensed three clinical-stage assets for undisclosed terms, including Ionis’ tonlamarsen and Sanofi’s ataciguat , according to past Endpoints News reports. Kardigan is now saying it also got the exclusive worldwide rights to danicamtiv, which was discovered by MyoKardia, the cardio company acquired by Bristol Myers Squibb. Tassos Gianakakos, who is Kardigan’s CEO, previously was the chief executive of MyoKardia, steering the company to a $13 billion exit in 2020. Kardigan emerged with $300 million in January . — Kyle LaHucik 💉 Eli Lilly halts muscle-sparing diabetes study: The drugmaker called off a Phase 2 trial of its muscle-building product bimagrumab in combination with its obesity shot Zepbound, according to the federal clinical trials register. The trial intended to enroll patients with both obesity and type 2 diabetes, but Lilly terminated it for “strategic business reasons.” A spokesperson said the company routinely evaluates its clinical development programs “to optimize the potential for each product.” Another mid-stage trial of bimagrumab in nondiabetic obesity patients, again in combination with Zepbound, could report in the second quarter of next year. The activin/myostatin type II inhibitor has already shown promise in Phase 2 when used alongside Novo Nordisk’s GLP-1 Wegovy. — Elizabeth Cairns 💰 UniQure launches $200M offering: The company set out to raise the money after reporting new positive data from its Huntington’s disease gene therapy. UniQure shares $QURE were up nearly 250% at market close on Wednesday. — Max Gelman 📈 MBX Biosciences’ $199M offering: The company is selling about 11.1 million shares at $18 apiece. Earlier this week, MBX disclosed Phase 2 data for its experimental hypoparathyroidism treatment. — Jaimy Lee 📝 KalVista’s $125M offering: The company plans to use the proceeds from the offering of convertible senior notes to fund the commercialization of Ekterly , its newly approved hereditary angioedema drug. — Jaimy Lee 💵 Volastra adds $30M to Series A: The New York biotech reeled in the additional funds from “all key existing investors,” a Volastra spokesperson told Endpoints News , confirming the details of an SEC filing . The startup in 2023 disclosed a $60 million Series A from Polaris, ARCH Venture Partners and Eli Lilly, among others. The cancer biotech in May presented data on its KIF18A inhibitor VLS-1488. It also has the rights to an Amgen oncology drug. — Kyle LaHucik 💊 Basilea Pharmaceutica’s new government funding: The company has been awarded a BARDA contract to advance a Phase 3 oral antibiotic for complicated urinary tract infections. Basilea recently acquired the global rights to the antibiotic, which is called ceftibuten-ledaborbactam etzadroxil, from Venatorx. It’s getting $6 million upfront, with up to $153 million in milestones on the table. — Anna Brown 🏦 Gossamer Bio to acquire Respira Therapeutics in all-stock deal: The buyout will net Gossamer a program called RT234, which is being studied for pulmonary hypertension. RT234 is an inhaled version of the generic drug vardenafil, a PDE5 inhibitor. Gossamer plans to seek an approval through the 505(b)(2) regulatory pathway, though it may not start new clinical trials until 2027. Gossamer’s stock $GOSS was down about 7% on Thursday morning. — Max Gelman 💸 Sanofi invests $25M in Immuneering: The French drugmaker purchased $25 million worth of Immuneering’s stock as part of a public offering. Immuneering on Wednesday reported additional positive data for its experimental pancreatic cancer drug. It intends to use the money from the offering on preclinical and clinical studies. — Max Gelman 💼 Heidelberg Pharma is laying off 75% of its staff: The German biotech said it hasn’t yet received $70 million for a milestone stemming from a deal with HealthCare Royalty, saying the “condition had not been met.” To conserve cash, it will now focus on developing its antibody-drug conjugate HDP-101, and it’s pausing work on another one called HDP-102 and discontinuing all early research. Heidelberg has 116 employees at the end of 2024. It had €22.9 million in cash as of Aug. 31. — Jaimy Lee

AcquisitionPhase 3Phase 2

04 Sep 2025

·www.prnewswire.com

Late Breaking Clinical Research Coming to Heart Failure Society of America Annual Scientific Meeting September 26-29

WASHINGTON, Sept. 4, 2025 /PRNewswire/ -- The Heart Failure Society of America (HFSA) is pleased to announce the Late Breaking Clinical Research that will be presented at its Annual Scientific Meeting (ASM), September 26-29, at the at the Minneapolis Convention Center in Minneapolis, MN. Late breaking clinical research to be featured during two plenary sessions includes results and updates from these major randomized trials: Continue Reading Heart Failure Society of America Annual Scientific Meeting 2025 takes place September 26-29 in Minneapolis, MN. Sunday, September 28 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 1: Devices and Cardiomyopathies Integra-D Trial Effects of a Novel Cardiac Contractility Modulation-Defibrillator (CCM-D) on NYHA Functional Class in ICD-Indicated Patients: Post-Implant Results from the Integra-D Trial FUTURE-HF Development of an Individualized Congestion Score using a Novel Implantable Inferior Vena Cava Sensor: the FUTURE-HF Trial Portfolio DETECT-HF Development and Training of a Voice-Based Algorithm for Heart Failure Monitoring: Performance results from 599 Patients over 360,000 Patient-Days FOREST-HCM Safety and Efficacy of Aficamten in Patients with Nonobstructive Hypertrophic Cardiomyopathy: a 96-week analysis from FOREST-HCM MAPLE-HCM Divergent Effect of Aficamten Versus Metoprolol on Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM ATTRibute-CM Acoramidis Reduces Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM HELIOS-B Reduction in Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran Compared with Placebo: Analysis from HELIOS-B Monday, September 29 Plenary Session | 9:00 AM – 10:30 AM Late Breaking Clinical Research 2: Novel Therapies VICTOR Trial Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients with HFrEF Enrolled in the VICTOR trial Tolerability and Safety of Vericiguat in Chronic Heart Failure with Reduced Ejection Fraction SEISMiC C Safety and Efficacy of Intravenous Administration of Istaroxime for 48 hours in Patients with SCAI C Cardiogenic Shock due to Acute Heart Failure SUMMIT Trial Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis from the SUMMIT Trial GARDEN TIMI-74 GDF-15 Neutralization in Patients with Heart Failure: Primary Results of the GARDEN-TIMI 74 Trial Danicamtiv Trial Danicamtiv Restores Ventricular and Atrial Function in Patients with Dilated Cardiomyopathy Caused by Genetic Variants that Depress Sarcomere Function Late Breaking Clinical Research showcases novel results of major randomized trials and rapidly evolving research. Due to the quantity of remarkable trials submitted, HFSA will also feature late breaking research through Rapid Fire Oral Sessions. These Rapid Fire sessions are fast-paced oral presentations spotlighting key data from late breaking clinical research. Sessions take place on Sunday and Monday with Q&A and new topics each day. Sunday September 28 | Rapid Fire 1 | 10:45 AM - 11:45 AM Phase 1 Study of Daratumumab-Hyaluronidase for Reduction of Circulating Antibodies in Patients with High Allosensitization Awaiting Heart Transplantation Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Post-Heart Transplant Patients: A Multi-Center Retrospective Cohort Study Long Term Outcomes after LVAD Weaning for Myocardial Recovery: Results from the VAD Wean Recovery Network First-In-Human Implantation of a Next-Generation Membrane-Based LVAD Long Term Trajectory of Glomerular Filtration Rate Post-LAVD and the Impact on Clinical Outcomes: An analysis of the MOMEMTUM 3 Study Increased LVEF at Six Months Following LVAD Implant is Associated with Improved Long-Term Outcomes - A MOMENTUM-3 Analysis Screening for advanced heart failure in stable outpatients (The SAINTS study) Sunday, September 28 | Rapid Fire 2: | 2:15 PM - 3:15 PM Clinical Outcomes for Heart Failure at High Risk of Hyperkalemia according to Optimization of Agents Targeting the Renin-Angiotensin-Aldosterone System Intravenous Ferric Carboxymaltose in Patients With Ischemic Versus Non-Ischemic Etiology of Heart Failure and Iron Deficiency Residual Risk of Hyperkalemia Among Patients with Heart Failure Treated with SGLT2i and ARNI Instead of ACEI/ARB High-Dose IV Loop Diuretic Therapy and Ototoxicity Risk in Patients with Acute Heart Failure: Insights from the FASTR Trial Expanded Results from a Guideline-Directed Medical Therapy Clinic Optimized Heart Failure Therapy in Patients at Risk of Cardiac Wasting in Patients with Advanced Cancer: Results from the EMPATICC trial Supervised Exercise Training Improves Outcomes in Heart Failure: Evidence from the PACT-HF 2×2 Factorial Trial Sunday, September 28 | Rapid Fire 3 | 4:15 PM - 5:15 PM Cardiac Contractility Modulation Reduces Mortality and Heart Failure Hospitalizations: A Matched Comparison of Patients Receiving and Not Receiving CCM Derived from a Real-World Dataset PROACTIVE-HF: 2-year outcomes, stratified by LVEF Outcomes of Poor Clinical Responders After Transcatheter Aortic Valve Replacement in Older Patients Invasive Hemodynamic Risk Stratification and Transcatheter Edge-to-Edge Tricuspid Repair: One-Year Results from TRILUMINATE Pivotal Trial Relationship between changes in seated pulmonary artery pressure, blood pressure, heart rate, and weight prior to heart failure hospitalization A Randomized Trial of a Remote, Digital Intervention Targeting Heart Failure Medical Therapy Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-invasive Multisensor Device Deep learning assisted prediction for occurrence of pacing-induced cardiomyopathy in the atrio-ventricular block Monday, September 29 | Rapid Fire 4 | 12:00 PM – 1:00 PM Effect of vericiguat, compared with placebo, across baseline risk categories in chronic heart failure with reduced ejection fraction in the VICTOR Trial Effect of Vericiguat on Heart Failure Hospitalisation Events in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Effect of Vericiguat on Mortality in Ambulatory Patients with Heart Failure and Reduced Ejection Fraction: VICTOR Trial Prespecified Analysis Regional Variation in Outcomes and Response to Vericiguat in Heart Failure with Reduced Ejection Fraction: The VICTOR Trial Effect of the Soluble Guanylate Cyclase Stimulator Vericiguat on Health Status in the Phase 3 VICTOR Trial The Effect of Vericiguat on Mode of Death in Patients with Heart Failure with Reduced Ejection Fraction in the VICTOR Trial Rapidity of benefit of simultaneous initiation of finerenone and empagliflozin in people with chronic kidney disease and type 2 diabetes: the CONFIDENCE trial Dapagliflozin in Patients with Heart Failure: A Meta-Analysis of DAPA-HF, DELIVER, and DAPA ACT HF-TIMI 68 The meeting kicks off in just three weeks. A full schedule at a glance is available online, as well as information on the science and research and networking available at the meeting. Learn more about the meeting and register at hfsa.org/asm2025. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. Media Contact: Laura Poko, 301-798-4493, ext. 226, [email protected] SOURCE Heart Failure Society of America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 3Phase 1

100 Deals associated with Danicamtiv

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Familial Dilated Cardiomyopathy	Phase 3	-	Kardigan, Inc.	01 Nov 2025
Cardiomyopathy, Dilated	Phase 2	France	Bristol Myers Squibb Co.	06 Feb 2018
Cardiomyopathy, Dilated	Phase 2	Netherlands	Bristol Myers Squibb Co.	06 Feb 2018
Cardiomyopathy, Dilated	Phase 2	Poland	Bristol Myers Squibb Co.	06 Feb 2018
Cardiomyopathy, Dilated	Phase 2	Sweden	Bristol Myers Squibb Co.	06 Feb 2018
Heart failure with reduced ejection fraction	Phase 2	United States	Bristol Myers Squibb Co.	06 Feb 2018
Heart failure with reduced ejection fraction	Phase 2	France	Bristol Myers Squibb Co.	06 Feb 2018
Heart failure with reduced ejection fraction	Phase 2	Germany	Bristol Myers Squibb Co.	06 Feb 2018
Heart failure with reduced ejection fraction	Phase 2	Netherlands	Bristol Myers Squibb Co.	06 Feb 2018
Heart failure with reduced ejection fraction	Phase 2	Poland	Bristol Myers Squibb Co.	06 Feb 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04572893 (Literature \| Company_Website) Manual	Phase 2	Cardiomyopathy, Dilated	41	Danicamtiv (MYH7 cohort)	jojtkcdgpu(bsflrsexkx) = qrfnlxqfpj vhwszjapge (qyymaqasqn )	Positive	29 Sep 2025
				Danicamtiv (TTN cohort)	jojtkcdgpu(bsflrsexkx) = omhfvqvydt vhwszjapge (qyymaqasqn )
NCT03447990 (Pubmed \| Eur J Heart Fail) Manual	Phase 2	Heart Failure	40	Danicamtiv	xwpjaezxml(digjkwpckb) = xbkpumwhqu erwmzbzssk (rulukfkkde ) View more	Positive	01 Sep 2020
				Placebo	xwpjaezxml(digjkwpckb) = zvocufwxaj erwmzbzssk (rulukfkkde )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis